Treatments compared for pediatric-onset multiple sclerosis

Summary by Ground News
More patients with POMS are free of new or newly enlarging lesions with dimethyl fumarate. The annualized relapse rate is lower with DMF, according to a study in JAMA. Suicide risk is highest in the first three months after the dementia diagnosis.
2 months ago·Billings, United States

News Articles

More Filters
All
Left
Center
Right

Treatments compared for pediatric-onset multiple sclerosis

More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.

2 months ago
Read Full Article

Treatments Compared for Pediatric-Onset Multiple Sclerosis

THURSDAY, Oct. 6, 2022 (HealthDay News) -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate

2 months ago
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

100% of the sources are Center
Medical Xpress
C 100%
See less detail